A Study to Evaluate TG4050 in Ovarian Carcinoma

Overview

About this study

The purpose of this study is to evaluate the safety and tolerability, as well as some activity parameters, of TG4050 in patients with ovarian, fallopian or peritoneal serous carcinoma.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria: 

Screening period

  • Signed written informed consent in accordance to ICH-GCP and national/local regulation before any protocol-related procedures that are not part of normal patient care.
  • Female patients ≥ 18 years of age
  • Histologically confirmed high grade, stage IIIC or stage IVA (FIGO staging) serous ovarian, fallopian or primary peritoneal carcinoma.
  • Patients who have undergone primary debulking surgery and completed standard first-line platinum-based chemotherapy (at least 5 cycles of taxane-platinum combination) for whom tumor tissue has been banked from previous abdominal debulking surgery.
  • Patients must have achieved a complete response to therapy, as demonstrated by no residual disease on most recent CT scan and normal CA-125 not increasing by > 25% from nadir.
  • Patient who remains disease free at least 6 months from last prior dose of cytotoxic chemotherapy (maintenance therapy with bevacizumab or a PARP inhibitor is allowed).
  • Available tumor tissue and peripheral blood samples for exome and transcriptome sequencing.

Treatment period

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at treatment period initiation
  • Patients who have developed an asymptomatic relapse as defined by CA-125 ≥ 2 times ULN on 2 occasions at least 1 week apart (GCIG criteria) or low volume radiological disease and CA-125 > ULN. Low volume radiological disease is defined as radiologically visible disease excluding intra-hepatic or splenic metastases, ascites or pleural effusion thought to require drainage.
  • Adequate hematological, hepatic and renal functions:
    • Hemoglobin ≥ 9.0 g/dL;
    • Neutrophils count ≥ 1.5 x10^9/L;
    • Lymphocytes count ≥ 0.9 x10^9/L;
    • Platelets count ≥ 100 x10^9/L;
    • Total bilirubin ≤ 1.5 x ULN (except for patients with Gilbert’s syndrome) ;
    • Aspartate aminotransferase (AST) ≤ 2.5 x ULN;
    • Calculated creatinine clearance ≥ 45 mL/min using the Cockroft & Gault formula.
  • Patients who received standard maintenance therapy will stop before initiation of TG4050 administration. A free-interval of at least 30 days will be respected before first dosing of TG4050 except for Olaparib (at least 14 days).

Exclusion Criteria: 

Screening period

  • Patient having received:
    • Neoadjuvant chemotherapy prior to debulking surgery;
    • Any cancer immunotherapy including cancer vaccines, any antibody/drug targeting T cell co-regulatory proteins such as anti-PD1, anti-PDL1 or anti-CTLA-4.
  • Patients with other active malignancy ≤ 3 years prior to registration except non-melanoma skin cancer, and stage 0 in situ carcinoma. If there is an history of prior malignancy, patient must not be receiving other specific treatment for their cancer.
  • Patient post-organ transplantation, including allogeneic stem cell or bone marrow transplantation
  • Known history of positive testing for Human Immunodeficiency Virus (HIV) or known AIDS (Acquired Immune Deficiency Syndrome)
  • Any known allergy or reaction to eggs or attributed to compounds of similar chemical or biological composition to therapeutic vaccines/immunotherapeutic products
  • Acute or chronic infection with hepatitis C Virus (HCV) or Hepatitis B Virus (HBV).

Treatment period

  • Measurable disease according to RECIST 1.1.
  • Major surgery within 4 weeks prior to treatment start.
  • Treatment with another investigational agent within 30 days prior to TG4050 treatment initiation.
  • Patients under chronic treatment with systemic corticosteroids or other immunosuppressive drugs for a period of at least 4 weeks and whose treatment was not stopped 2 weeks prior to TG4050 treatment initiation planned date, with the exception of patients with adrenal insufficiency who may continue corticosteroids at physiological replacement dose, equivalent to ≤ 10 mg prednisone daily. Steroids with no or minimal systemic effect (topical, inhalation) are allowed.
  • Vaccination for the prevention of infectious diseases with a live vaccine during the four-week period prior to TG4050 treatment initiation planned date. Furthermore, patients should not receive any live vaccine during the period of study treatment administration.
  • Patient with any underlying medical condition, that in the opinion of the investigator, could make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety or toxicity of the study treatment.
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/social circumstances that could limit compliance with study requirements.
  • History of myocardial infarction ≤ 6 months.

 

 

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Matthew Block, M.D., Ph.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Mahesh Seetharam, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Jacksonville, Fla.

Mayo Clinic principal investigator

Gerardo Colon-Otero, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20470626

Mayo Clinic Footer